Haque Azizul, Pant Anudeep B
One Medical Center Drive, Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
New Orleans East Hospital, 5620 Read Blvd, New Orleans, LA 70127, USA.
Vaccines (Basel). 2020 Dec 6;8(4):739. doi: 10.3390/vaccines8040739.
The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.
新型冠状病毒SARS-CoV-2在全球的迅速传播构成了令人生畏的突发公共卫生事件。针对这一全球健康困境，人们采取了不同的预防措施；其中，疫苗研发处于前沿。为研发针对SARS-CoV-2的疫苗，已应用了几种先进的设计，并且已有44种候选疫苗进入临床试验阶段。目前尚不清楚哪些疫苗能达到有效性和安全性目标，不过有几种疫苗正准备在美国和欧洲获得紧急批准。本手稿讨论了各种疫苗平台的优缺点，并对处于前期阶段的疫苗的安全性和有效性进行了评估。一旦研发出疫苗，接下来的挑战将是获取、部署和接种。本手稿详细描述了这些挑战，并针对大量转化挑战提出了解决方案。从SARS-CoV-2的流行病学情况可以明显看出，只要该病毒仍在少数地区传播，它就会对每个人构成威胁。我们需要价格亲民、产量充足、可供世界各个角落使用的疫苗。
